Pre-made Imsidolimab benchmark antibody ( Whole mAb, anti-IL36R/IL1RL2 therapeutic antibody, Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP), EGFRi-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
| Products Name (INN Index) | Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody |
|---|---|
| INN Name | Imsidolimab |
| Target | IL36R |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | AnaptysBio |
| Conditions Approved | NA |
| Conditions Active | Generalised pustular psoriasis,Localised pustular psoriasis |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL36R |
| Package |
